je.st
news
Tag: fda
Mercks BRIDION (sugammadex) Receives FDA Approval for the Reversal of Neuromuscular Blockade Induced by Rocuronium and Vecuronium in Adults Undergoing Surgery
2015-12-17 23:52:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved BRIDION (sugammadex) Injection 100 mg/mL (equivalent to 108.8 mg/mL sugammadex sodium) for the reversal of neuromuscular blockade (NMB) induced by rocuronium bromide and vecuronium bromide in adults undergoing surgery. Language: English Contact: MerckMedia Contacts:Pamela Eisele, 267-305-3558Doris Li, 908-740-1903orInvestor Contacts:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 read more
Tags: approval
adults
surgery
induced
FDA approves cheaper version of Sanofi's bestselling insulin; it's from Eli Lilly, Boehringer
2015-12-17 01:17:36| Biotech - Topix.net
Federal health officials have approved a cheaper version of the world's top-selling insulin from Sanofi for millions of U.S. patients with diabetes. The Food and Drug Administration approved a new form of Sanofi's pen-like injector, Lantus, from drugmakers Eli Lilly and Co.
Tags: version
cheaper
eli
bestselling
FDA Issues Warning Letters\n
2015-12-16 06:00:00| Happi Breaking News
Dr. Brandt and Episcience hear from the Agency.
Tags: issues
warning
fda
issues warning
FDA Approves Expanded Age Indication for GARDASIL 9 in Males
2015-12-15 23:07:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. GARDASIL 9 Now Approved for Males 16 through 26 Years of Age for the Prevention of Anal Cancers and Genital Warts Caused by Nine HPV types KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orDeb Wambold, 215-652-2913orInvestors:Teri Loxam, 908-740-1986orJustin Holko, 908-740-1879 Media Capsule: Please Activate Javascript !function(d, s, id){var js,fjs=d.getElementsByTagName(s)[0],p=/^http:/.test(d.location)?'http':'https',dt=new Date().getTime();if(!d.getElementById(id)){js=d.createElement(s);js.id=id;js.src=p+"://s3.amazonaws.com/contentcapsule.com/clients/Merck/tags/4ef0f659-dc5f-471f-a926-02d1aa18adfe_reg_frame.js?dt="+dt;fjs.parentNode.insertBefore(js,fjs);}}(document,"script","contentcapsule-embed-4ef0f659-dc5f-471f-a926-02d1aa18adfe"); read more
Tags: in
age
expanded
indication
FDA panel rejects Merck claim Zetia/Vytorin cut heart risk
2015-12-15 10:29:34| Biotech - Topix.net
Dec 14 Merck & Co should not be allowed to claim that its cholesterol-lowering drugs Zetia and Vytorin reduce the risk of heart attacks and strokes in patients with coronary heart disease, an advisory committee to the U.S. Food and Drug Administration concluded on Monday.
Sites : [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] next »